JP2014012683A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014012683A5 JP2014012683A5 JP2013166370A JP2013166370A JP2014012683A5 JP 2014012683 A5 JP2014012683 A5 JP 2014012683A5 JP 2013166370 A JP2013166370 A JP 2013166370A JP 2013166370 A JP2013166370 A JP 2013166370A JP 2014012683 A5 JP2014012683 A5 JP 2014012683A5
- Authority
- JP
- Japan
- Prior art keywords
- ige
- fab
- pharmaceutical composition
- atopic
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010003645 Atopy Diseases 0.000 claims description 15
- 208000024891 symptom Diseases 0.000 claims description 9
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 102000009438 IgE Receptors Human genes 0.000 claims description 4
- 108010073816 IgE Receptors Proteins 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 3
- 230000002052 anaphylactic effect Effects 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 2
- 230000003993 interaction Effects 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 6
- 210000003651 basophil Anatomy 0.000 description 5
- 208000006673 asthma Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0101093A SE0101093D0 (sv) | 2001-03-28 | 2001-03-28 | Novel compound for treatment of allergy and asthma |
| SE0101093-3 | 2001-03-28 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002577880A Division JP2005500992A (ja) | 2001-03-28 | 2002-03-28 | アレルギーおよび喘息の治療用新規化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014012683A JP2014012683A (ja) | 2014-01-23 |
| JP2014012683A5 true JP2014012683A5 (OSRAM) | 2015-03-05 |
Family
ID=20283563
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002577880A Pending JP2005500992A (ja) | 2001-03-28 | 2002-03-28 | アレルギーおよび喘息の治療用新規化合物 |
| JP2013166370A Pending JP2014012683A (ja) | 2001-03-28 | 2013-08-09 | アレルギーおよび喘息の治療用新規化合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002577880A Pending JP2005500992A (ja) | 2001-03-28 | 2002-03-28 | アレルギーおよび喘息の治療用新規化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US6986889B2 (OSRAM) |
| EP (1) | EP1373322A1 (OSRAM) |
| JP (2) | JP2005500992A (OSRAM) |
| AU (1) | AU2002251624B8 (OSRAM) |
| CA (1) | CA2441048C (OSRAM) |
| SE (1) | SE0101093D0 (OSRAM) |
| WO (1) | WO2002079257A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6884877B2 (en) | 2001-10-03 | 2005-04-26 | Florida State University Research Foundation, Inc. | Purified linear epitopes from cashew nuts, nucleic acids encoding therefor, and associated methods |
| US8137670B2 (en) * | 2005-09-29 | 2012-03-20 | Medimmune, Llc | Method of identifying membrane IgE specific antibodies and use thereof for targeting IgE producing precursor cells |
| US10196458B2 (en) | 2013-07-26 | 2019-02-05 | The Regents Of The University Of California | Anti-immunoglobulin E antibodies and methods of using thereof |
| JP2025533898A (ja) * | 2022-10-07 | 2025-10-09 | アブウィズ バイオ，インコーポレイテッド | 抗ｉｇｅ抗体 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5449760A (en) * | 1987-12-31 | 1995-09-12 | Tanox Biosystems, Inc. | Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| JP3156237B2 (ja) * | 1991-12-24 | 2001-04-16 | 雪印乳業株式会社 | 抗ヒトＩｇＥ モノクローナル抗体 |
| US6037453A (en) * | 1995-03-15 | 2000-03-14 | Genentech, Inc. | Immunoglobulin variants |
| GB9908533D0 (en) * | 1999-04-14 | 1999-06-09 | Novartis Ag | Organic compounds |
| WO2000072879A1 (en) | 1999-05-26 | 2000-12-07 | Tanox, Inc. | TREATING ALLERGIC DISEASES WITH IMMUNOTHERAPY AND IgE ANTAGONISTS |
-
2001
- 2001-03-28 SE SE0101093A patent/SE0101093D0/xx unknown
-
2002
- 2002-03-28 EP EP02720698A patent/EP1373322A1/en not_active Ceased
- 2002-03-28 WO PCT/SE2002/000636 patent/WO2002079257A1/en not_active Ceased
- 2002-03-28 CA CA2441048A patent/CA2441048C/en not_active Expired - Lifetime
- 2002-03-28 US US10/108,301 patent/US6986889B2/en not_active Ceased
- 2002-03-28 JP JP2002577880A patent/JP2005500992A/ja active Pending
- 2002-03-28 AU AU2002251624A patent/AU2002251624B8/en not_active Expired
-
2010
- 2010-04-09 US US12/757,821 patent/USRE42324E1/en not_active Expired - Lifetime
-
2013
- 2013-08-09 JP JP2013166370A patent/JP2014012683A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11325972B2 (en) | Methods of treatment of eosinophilic bronchitis with an anti-IL-5 antibody | |
| Kanwar et al. | Pemphigus in India | |
| KR20200070355A (ko) | 발작성 야간 혈색소뇨 (pnh) 및 비정형 용혈성 요독 증후군 (ahus)의 치료를 위한 항-c5 항체의 투여량 및 투여 | |
| US11976113B2 (en) | Biopharmaceutical compositions comprising nucleic acids encoding IL-5 binding proteins | |
| CA2825986C (en) | Arthritis treatment | |
| JP2018515493A5 (OSRAM) | ||
| オオグシフミタカ et al. | Autoantibodies to IL-1α in sera from rapidly progressive idiopathic pulmonary fibrosis | |
| US20240209097A1 (en) | Treatment regimens | |
| JP2014012683A5 (OSRAM) | ||
| Daeschlein et al. | Repetitive immunoadsorption cycles for treatment of severe atopic dermatitis | |
| RU2006113701A (ru) | Лечение респираторных заболеваний антителами против рецептора il-2 | |
| Mitchell et al. | Anti-IgE and biologic approaches for the treatment of asthma | |
| CN101199845B (zh) | 一种稳定的抗IgE人源化单抗制剂 | |
| US20230365712A1 (en) | Notch4 antibodies and uses thereof | |
| Tada et al. | Characterization of anti-SARS-CoV-2 monoclonal antibodies focusing on antigen binding, neutralization, and FcγR activation via formation of immune complex | |
| Syabbalo | Clinical Features and Management of Eosinophilic Asthma | |
| Güvenir et al. | The importance of IgE and the uses of anti-IgE | |
| US20200055942A1 (en) | Treatment regimens | |
| Mahashur | Role of Biologics in Asthma | |
| WO2019025847A1 (en) | TREATMENT DIAGRAMS | |
| CN118488851A (zh) | 特应性皮炎的治疗 | |
| WO2021255648A1 (en) | Hyperimmune globulins for treatment of influenza a | |
| Rokni et al. | Effects of metformin on autoimmune immunoglobins and interferon-c in patients with early diagnosed pemphigus vulgaris: a prospective clinical trial | |
| Fick et al. | Efficacy and Safety of Xolair Anti-IgE Monoclonal Antibody in Adult Asthmatics | |
| WO2005069717A2 (en) | The use os anti-rh antibodies for treating acute thrombocytopenia associated with dengue hemorrhagic fever, hepatitis c and other microbial infections |